Appili Therapeutics Inc.
APLIF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | -$0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -87.9% | 147.6% | -76% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 359% | -249.8% | -2,425.1% | -1,690.7% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -2,613.1% | -457% | -2,765.9% | -1,806.2% |
| EPS Diluted | -0.022 | -0.031 | -0.081 | -0.376 |
| % Growth | 30.8% | 61.6% | 78.4% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | -$0 | -$0 | -$0 |